Report Overview
Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
The global Neurometabolic Disorders market size was estimated at USD 1254 million in 2023 and is projected to reach USD 1863.56 million by 2032, exhibiting a CAGR of 4.50% during the forecast period.
North America Neurometabolic Disorders market size was estimated at USD 352.45 million in 2023, at a CAGR of 3.86% during the forecast period of 2025 through 2032.
This report provides a deep insight into the global Neurometabolic Disorders market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neurometabolic Disorders Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neurometabolic Disorders market in any manner.
Global Neurometabolic Disorders Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Market Segmentation (by Type)
Gaucher
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Neurometabolic Disorders
1.2 Key Market Segments
1.2.1 Neurometabolic Disorders Segment by Type
1.2.2 Neurometabolic Disorders Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Neurometabolic Disorders Market Overview
2.1 Global Market Overview
2.1.1 Global Neurometabolic Disorders Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Neurometabolic Disorders Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Neurometabolic Disorders Market Competitive Landscape
3.1 Global Neurometabolic Disorders Sales by Manufacturers (2019-2025)
3.2 Global Neurometabolic Disorders Revenue Market Share by Manufacturers (2019-2025)
3.3 Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Neurometabolic Disorders Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Neurometabolic Disorders Sales Sites, Area Served, Product Type
3.6 Neurometabolic Disorders Market Competitive Situation and Trends
3.6.1 Neurometabolic Disorders Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neurometabolic Disorders Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Neurometabolic Disorders Industry Chain Analysis
4.1 Neurometabolic Disorders Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Neurometabolic Disorders Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Neurometabolic Disorders Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurometabolic Disorders Sales Market Share by Type (2019-2025)
6.3 Global Neurometabolic Disorders Market Size Market Share by Type (2019-2025)
6.4 Global Neurometabolic Disorders Price by Type (2019-2025)
7 Neurometabolic Disorders Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurometabolic Disorders Market Sales by Application (2019-2025)
7.3 Global Neurometabolic Disorders Market Size (M USD) by Application (2019-2025)
7.4 Global Neurometabolic Disorders Sales Growth Rate by Application (2019-2025)
8 Neurometabolic Disorders Market Consumption by Region
8.1 Global Neurometabolic Disorders Sales by Region
8.1.1 Global Neurometabolic Disorders Sales by Region
8.1.2 Global Neurometabolic Disorders Sales Market Share by Region
8.2 North America
8.2.1 North America Neurometabolic Disorders Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neurometabolic Disorders Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Neurometabolic Disorders Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neurometabolic Disorders Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neurometabolic Disorders Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Neurometabolic Disorders Market Production by Region
9.1 Global Production of Neurometabolic Disorders by Region (2019-2025)
9.2 Global Neurometabolic Disorders Revenue Market Share by Region (2019-2025)
9.3 Global Neurometabolic Disorders Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Neurometabolic Disorders Production
9.4.1 North America Neurometabolic Disorders Production Growth Rate (2019-2025)
9.4.2 North America Neurometabolic Disorders Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Neurometabolic Disorders Production
9.5.1 Europe Neurometabolic Disorders Production Growth Rate (2019-2025)
9.5.2 Europe Neurometabolic Disorders Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Neurometabolic Disorders Production (2019-2025)
9.6.1 Japan Neurometabolic Disorders Production Growth Rate (2019-2025)
9.6.2 Japan Neurometabolic Disorders Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Neurometabolic Disorders Production (2019-2025)
9.7.1 China Neurometabolic Disorders Production Growth Rate (2019-2025)
9.7.2 China Neurometabolic Disorders Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Amicus Therapeutics
10.1.1 Amicus Therapeutics Neurometabolic Disorders Basic Information
10.1.2 Amicus Therapeutics Neurometabolic Disorders Product Overview
10.1.3 Amicus Therapeutics Neurometabolic Disorders Product Market Performance
10.1.4 Amicus Therapeutics Business Overview
10.1.5 Amicus Therapeutics Neurometabolic Disorders SWOT Analysis
10.1.6 Amicus Therapeutics Recent Developments
10.2 ISU Abxis
10.2.1 ISU Abxis Neurometabolic Disorders Basic Information
10.2.2 ISU Abxis Neurometabolic Disorders Product Overview
10.2.3 ISU Abxis Neurometabolic Disorders Product Market Performance
10.2.4 ISU Abxis Business Overview
10.2.5 ISU Abxis Neurometabolic Disorders SWOT Analysis
10.2.6 ISU Abxis Recent Developments
10.3 JCR Pharmaceuticals
10.3.1 JCR Pharmaceuticals Neurometabolic Disorders Basic Information
10.3.2 JCR Pharmaceuticals Neurometabolic Disorders Product Overview
10.3.3 JCR Pharmaceuticals Neurometabolic Disorders Product Market Performance
10.3.4 JCR Pharmaceuticals Neurometabolic Disorders SWOT Analysis
10.3.5 JCR Pharmaceuticals Business Overview
10.3.6 JCR Pharmaceuticals Recent Developments
10.4 Biosidus
10.4.1 Biosidus Neurometabolic Disorders Basic Information
10.4.2 Biosidus Neurometabolic Disorders Product Overview
10.4.3 Biosidus Neurometabolic Disorders Product Market Performance
10.4.4 Biosidus Business Overview
10.4.5 Biosidus Recent Developments
10.5 Greenovation Biotech
10.5.1 Greenovation Biotech Neurometabolic Disorders Basic Information
10.5.2 Greenovation Biotech Neurometabolic Disorders Product Overview
10.5.3 Greenovation Biotech Neurometabolic Disorders Product Market Performance
10.5.4 Greenovation Biotech Business Overview
10.5.5 Greenovation Biotech Recent Developments
10.6 UAB Proforma
10.6.1 UAB Proforma Neurometabolic Disorders Basic Information
10.6.2 UAB Proforma Neurometabolic Disorders Product Overview
10.6.3 UAB Proforma Neurometabolic Disorders Product Market Performance
10.6.4 UAB Proforma Business Overview
10.6.5 UAB Proforma Recent Developments
10.7 Dong-A Socio Group
10.7.1 Dong-A Socio Group Neurometabolic Disorders Basic Information
10.7.2 Dong-A Socio Group Neurometabolic Disorders Product Overview
10.7.3 Dong-A Socio Group Neurometabolic Disorders Product Market Performance
10.7.4 Dong-A Socio Group Business Overview
10.7.5 Dong-A Socio Group Recent Developments
10.8 ExSAR Corporation
10.8.1 ExSAR Corporation Neurometabolic Disorders Basic Information
10.8.2 ExSAR Corporation Neurometabolic Disorders Product Overview
10.8.3 ExSAR Corporation Neurometabolic Disorders Product Market Performance
10.8.4 ExSAR Corporation Business Overview
10.8.5 ExSAR Corporation Recent Developments
10.9 Lixte Biotechnology
10.9.1 Lixte Biotechnology Neurometabolic Disorders Basic Information
10.9.2 Lixte Biotechnology Neurometabolic Disorders Product Overview
10.9.3 Lixte Biotechnology Neurometabolic Disorders Product Market Performance
10.9.4 Lixte Biotechnology Business Overview
10.9.5 Lixte Biotechnology Recent Developments
10.10 Neuraltus Pharmaceuticals
10.10.1 Neuraltus Pharmaceuticals Neurometabolic Disorders Basic Information
10.10.2 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Overview
10.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Market Performance
10.10.4 Neuraltus Pharmaceuticals Business Overview
10.10.5 Neuraltus Pharmaceuticals Recent Developments
10.11 Protalix
10.11.1 Protalix Neurometabolic Disorders Basic Information
10.11.2 Protalix Neurometabolic Disorders Product Overview
10.11.3 Protalix Neurometabolic Disorders Product Market Performance
10.11.4 Protalix Business Overview
10.11.5 Protalix Recent Developments
10.12 Pharming Group
10.12.1 Pharming Group Neurometabolic Disorders Basic Information
10.12.2 Pharming Group Neurometabolic Disorders Product Overview
10.12.3 Pharming Group Neurometabolic Disorders Product Market Performance
10.12.4 Pharming Group Business Overview
10.12.5 Pharming Group Recent Developments
10.13 Protalix BioTherapeutics
10.13.1 Protalix BioTherapeutics Neurometabolic Disorders Basic Information
10.13.2 Protalix BioTherapeutics Neurometabolic Disorders Product Overview
10.13.3 Protalix BioTherapeutics Neurometabolic Disorders Product Market Performance
10.13.4 Protalix BioTherapeutics Business Overview
10.13.5 Protalix BioTherapeutics Recent Developments
10.14 Amicus
10.14.1 Amicus Neurometabolic Disorders Basic Information
10.14.2 Amicus Neurometabolic Disorders Product Overview
10.14.3 Amicus Neurometabolic Disorders Product Market Performance
10.14.4 Amicus Business Overview
10.14.5 Amicus Recent Developments
10.15 Biomarin
10.15.1 Biomarin Neurometabolic Disorders Basic Information
10.15.2 Biomarin Neurometabolic Disorders Product Overview
10.15.3 Biomarin Neurometabolic Disorders Product Market Performance
10.15.4 Biomarin Business Overview
10.15.5 Biomarin Recent Developments
10.16 Genzyme
10.16.1 Genzyme Neurometabolic Disorders Basic Information
10.16.2 Genzyme Neurometabolic Disorders Product Overview
10.16.3 Genzyme Neurometabolic Disorders Product Market Performance
10.16.4 Genzyme Business Overview
10.16.5 Genzyme Recent Developments
10.17 Shire
10.17.1 Shire Neurometabolic Disorders Basic Information
10.17.2 Shire Neurometabolic Disorders Product Overview
10.17.3 Shire Neurometabolic Disorders Product Market Performance
10.17.4 Shire Business Overview
10.17.5 Shire Recent Developments
10.18 Greencross
10.18.1 Greencross Neurometabolic Disorders Basic Information
10.18.2 Greencross Neurometabolic Disorders Product Overview
10.18.3 Greencross Neurometabolic Disorders Product Market Performance
10.18.4 Greencross Business Overview
10.18.5 Greencross Recent Developments
11 Neurometabolic Disorders Market Forecast by Region
11.1 Global Neurometabolic Disorders Market Size Forecast
11.2 Global Neurometabolic Disorders Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurometabolic Disorders Market Size Forecast by Country
11.2.3 Asia Pacific Neurometabolic Disorders Market Size Forecast by Region
11.2.4 South America Neurometabolic Disorders Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Neurometabolic Disorders by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Neurometabolic Disorders Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Neurometabolic Disorders by Type (2025-2032)
12.1.2 Global Neurometabolic Disorders Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Neurometabolic Disorders by Type (2025-2032)
12.2 Global Neurometabolic Disorders Market Forecast by Application (2025-2032)
12.2.1 Global Neurometabolic Disorders Sales (K MT) Forecast by Application
12.2.2 Global Neurometabolic Disorders Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neurometabolic Disorders Market Size Comparison by Region (M USD)
Table 5. Global Neurometabolic Disorders Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Neurometabolic Disorders Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Neurometabolic Disorders Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Neurometabolic Disorders Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurometabolic Disorders as of 2022)
Table 10. Global Market Neurometabolic Disorders Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Neurometabolic Disorders Sales Sites and Area Served
Table 12. Manufacturers Neurometabolic Disorders Product Type
Table 13. Global Neurometabolic Disorders Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Neurometabolic Disorders
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neurometabolic Disorders Market Challenges
Table 22. Global Neurometabolic Disorders Sales by Type (K MT)
Table 23. Global Neurometabolic Disorders Market Size by Type (M USD)
Table 24. Global Neurometabolic Disorders Sales (K MT) by Type (2019-2025)
Table 25. Global Neurometabolic Disorders Sales Market Share by Type (2019-2025)
Table 26. Global Neurometabolic Disorders Market Size (M USD) by Type (2019-2025)
Table 27. Global Neurometabolic Disorders Market Size Share by Type (2019-2025)
Table 28. Global Neurometabolic Disorders Price (USD/MT) by Type (2019-2025)
Table 29. Global Neurometabolic Disorders Sales (K MT) by Application
Table 30. Global Neurometabolic Disorders Market Size by Application
Table 31. Global Neurometabolic Disorders Sales by Application (2019-2025) & (K MT)
Table 32. Global Neurometabolic Disorders Sales Market Share by Application (2019-2025)
Table 33. Global Neurometabolic Disorders Sales by Application (2019-2025) & (M USD)
Table 34. Global Neurometabolic Disorders Market Share by Application (2019-2025)
Table 35. Global Neurometabolic Disorders Sales Growth Rate by Application (2019-2025)
Table 36. Global Neurometabolic Disorders Sales by Region (2019-2025) & (K MT)
Table 37. Global Neurometabolic Disorders Sales Market Share by Region (2019-2025)
Table 38. North America Neurometabolic Disorders Sales by Country (2019-2025) & (K MT)
Table 39. Europe Neurometabolic Disorders Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Neurometabolic Disorders Sales by Region (2019-2025) & (K MT)
Table 41. South America Neurometabolic Disorders Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Neurometabolic Disorders Sales by Region (2019-2025) & (K MT)
Table 43. Global Neurometabolic Disorders Production (K MT) by Region (2019-2025)
Table 44. Global Neurometabolic Disorders Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Neurometabolic Disorders Revenue Market Share by Region (2019-2025)
Table 46. Global Neurometabolic Disorders Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Neurometabolic Disorders Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Neurometabolic Disorders Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Neurometabolic Disorders Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Neurometabolic Disorders Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Amicus Therapeutics Neurometabolic Disorders Basic Information
Table 52. Amicus Therapeutics Neurometabolic Disorders Product Overview
Table 53. Amicus Therapeutics Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Amicus Therapeutics Business Overview
Table 55. Amicus Therapeutics Neurometabolic Disorders SWOT Analysis
Table 56. Amicus Therapeutics Recent Developments
Table 57. ISU Abxis Neurometabolic Disorders Basic Information
Table 58. ISU Abxis Neurometabolic Disorders Product Overview
Table 59. ISU Abxis Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. ISU Abxis Business Overview
Table 61. ISU Abxis Neurometabolic Disorders SWOT Analysis
Table 62. ISU Abxis Recent Developments
Table 63. JCR Pharmaceuticals Neurometabolic Disorders Basic Information
Table 64. JCR Pharmaceuticals Neurometabolic Disorders Product Overview
Table 65. JCR Pharmaceuticals Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. JCR Pharmaceuticals Neurometabolic Disorders SWOT Analysis
Table 67. JCR Pharmaceuticals Business Overview
Table 68. JCR Pharmaceuticals Recent Developments
Table 69. Biosidus Neurometabolic Disorders Basic Information
Table 70. Biosidus Neurometabolic Disorders Product Overview
Table 71. Biosidus Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Biosidus Business Overview
Table 73. Biosidus Recent Developments
Table 74. Greenovation Biotech Neurometabolic Disorders Basic Information
Table 75. Greenovation Biotech Neurometabolic Disorders Product Overview
Table 76. Greenovation Biotech Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Greenovation Biotech Business Overview
Table 78. Greenovation Biotech Recent Developments
Table 79. UAB Proforma Neurometabolic Disorders Basic Information
Table 80. UAB Proforma Neurometabolic Disorders Product Overview
Table 81. UAB Proforma Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. UAB Proforma Business Overview
Table 83. UAB Proforma Recent Developments
Table 84. Dong-A Socio Group Neurometabolic Disorders Basic Information
Table 85. Dong-A Socio Group Neurometabolic Disorders Product Overview
Table 86. Dong-A Socio Group Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Dong-A Socio Group Business Overview
Table 88. Dong-A Socio Group Recent Developments
Table 89. ExSAR Corporation Neurometabolic Disorders Basic Information
Table 90. ExSAR Corporation Neurometabolic Disorders Product Overview
Table 91. ExSAR Corporation Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. ExSAR Corporation Business Overview
Table 93. ExSAR Corporation Recent Developments
Table 94. Lixte Biotechnology Neurometabolic Disorders Basic Information
Table 95. Lixte Biotechnology Neurometabolic Disorders Product Overview
Table 96. Lixte Biotechnology Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 97. Lixte Biotechnology Business Overview
Table 98. Lixte Biotechnology Recent Developments
Table 99. Neuraltus Pharmaceuticals Neurometabolic Disorders Basic Information
Table 100. Neuraltus Pharmaceuticals Neurometabolic Disorders Product Overview
Table 101. Neuraltus Pharmaceuticals Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 102. Neuraltus Pharmaceuticals Business Overview
Table 103. Neuraltus Pharmaceuticals Recent Developments
Table 104. Protalix Neurometabolic Disorders Basic Information
Table 105. Protalix Neurometabolic Disorders Product Overview
Table 106. Protalix Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 107. Protalix Business Overview
Table 108. Protalix Recent Developments
Table 109. Pharming Group Neurometabolic Disorders Basic Information
Table 110. Pharming Group Neurometabolic Disorders Product Overview
Table 111. Pharming Group Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 112. Pharming Group Business Overview
Table 113. Pharming Group Recent Developments
Table 114. Protalix BioTherapeutics Neurometabolic Disorders Basic Information
Table 115. Protalix BioTherapeutics Neurometabolic Disorders Product Overview
Table 116. Protalix BioTherapeutics Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 117. Protalix BioTherapeutics Business Overview
Table 118. Protalix BioTherapeutics Recent Developments
Table 119. Amicus Neurometabolic Disorders Basic Information
Table 120. Amicus Neurometabolic Disorders Product Overview
Table 121. Amicus Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 122. Amicus Business Overview
Table 123. Amicus Recent Developments
Table 124. Biomarin Neurometabolic Disorders Basic Information
Table 125. Biomarin Neurometabolic Disorders Product Overview
Table 126. Biomarin Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 127. Biomarin Business Overview
Table 128. Biomarin Recent Developments
Table 129. Genzyme Neurometabolic Disorders Basic Information
Table 130. Genzyme Neurometabolic Disorders Product Overview
Table 131. Genzyme Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 132. Genzyme Business Overview
Table 133. Genzyme Recent Developments
Table 134. Shire Neurometabolic Disorders Basic Information
Table 135. Shire Neurometabolic Disorders Product Overview
Table 136. Shire Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 137. Shire Business Overview
Table 138. Shire Recent Developments
Table 139. Greencross Neurometabolic Disorders Basic Information
Table 140. Greencross Neurometabolic Disorders Product Overview
Table 141. Greencross Neurometabolic Disorders Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 142. Greencross Business Overview
Table 143. Greencross Recent Developments
Table 144. Global Neurometabolic Disorders Sales Forecast by Region (2025-2032) & (K MT)
Table 145. Global Neurometabolic Disorders Market Size Forecast by Region (2025-2032) & (M USD)
Table 146. North America Neurometabolic Disorders Sales Forecast by Country (2025-2032) & (K MT)
Table 147. North America Neurometabolic Disorders Market Size Forecast by Country (2025-2032) & (M USD)
Table 148. Europe Neurometabolic Disorders Sales Forecast by Country (2025-2032) & (K MT)
Table 149. Europe Neurometabolic Disorders Market Size Forecast by Country (2025-2032) & (M USD)
Table 150. Asia Pacific Neurometabolic Disorders Sales Forecast by Region (2025-2032) & (K MT)
Table 151. Asia Pacific Neurometabolic Disorders Market Size Forecast by Region (2025-2032) & (M USD)
Table 152. South America Neurometabolic Disorders Sales Forecast by Country (2025-2032) & (K MT)
Table 153. South America Neurometabolic Disorders Market Size Forecast by Country (2025-2032) & (M USD)
Table 154. Middle East and Africa Neurometabolic Disorders Consumption Forecast by Country (2025-2032) & (Units)
Table 155. Middle East and Africa Neurometabolic Disorders Market Size Forecast by Country (2025-2032) & (M USD)
Table 156. Global Neurometabolic Disorders Sales Forecast by Type (2025-2032) & (K MT)
Table 157. Global Neurometabolic Disorders Market Size Forecast by Type (2025-2032) & (M USD)
Table 158. Global Neurometabolic Disorders Price Forecast by Type (2025-2032) & (USD/MT)
Table 159. Global Neurometabolic Disorders Sales (K MT) Forecast by Application (2025-2032)
Table 160. Global Neurometabolic Disorders Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Neurometabolic Disorders
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurometabolic Disorders Market Size (M USD), 2019-2032
Figure 5. Global Neurometabolic Disorders Market Size (M USD) (2019-2032)
Figure 6. Global Neurometabolic Disorders Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurometabolic Disorders Market Size by Country (M USD)
Figure 11. Neurometabolic Disorders Sales Share by Manufacturers in 2023
Figure 12. Global Neurometabolic Disorders Revenue Share by Manufacturers in 2023
Figure 13. Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Neurometabolic Disorders Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Neurometabolic Disorders Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Neurometabolic Disorders Market Share by Type
Figure 18. Sales Market Share of Neurometabolic Disorders by Type (2019-2025)
Figure 19. Sales Market Share of Neurometabolic Disorders by Type in 2023
Figure 20. Market Size Share of Neurometabolic Disorders by Type (2019-2025)
Figure 21. Market Size Market Share of Neurometabolic Disorders by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neurometabolic Disorders Market Share by Application
Figure 24. Global Neurometabolic Disorders Sales Market Share by Application (2019-2025)
Figure 25. Global Neurometabolic Disorders Sales Market Share by Application in 2023
Figure 26. Global Neurometabolic Disorders Market Share by Application (2019-2025)
Figure 27. Global Neurometabolic Disorders Market Share by Application in 2023
Figure 28. Global Neurometabolic Disorders Sales Growth Rate by Application (2019-2025)
Figure 29. Global Neurometabolic Disorders Sales Market Share by Region (2019-2025)
Figure 30. North America Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Neurometabolic Disorders Sales Market Share by Country in 2023
Figure 32. U.S. Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Neurometabolic Disorders Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Neurometabolic Disorders Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Neurometabolic Disorders Sales Market Share by Country in 2023
Figure 37. Germany Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Neurometabolic Disorders Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Neurometabolic Disorders Sales Market Share by Region in 2023
Figure 44. China Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Neurometabolic Disorders Sales and Growth Rate (K MT)
Figure 50. South America Neurometabolic Disorders Sales Market Share by Country in 2023
Figure 51. Brazil Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Neurometabolic Disorders Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Neurometabolic Disorders Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Neurometabolic Disorders Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Neurometabolic Disorders Production Market Share by Region (2019-2025)
Figure 62. North America Neurometabolic Disorders Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Neurometabolic Disorders Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Neurometabolic Disorders Production (K MT) Growth Rate (2019-2025)
Figure 65. China Neurometabolic Disorders Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Neurometabolic Disorders Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Neurometabolic Disorders Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Neurometabolic Disorders Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Neurometabolic Disorders Market Share Forecast by Type (2025-2032)
Figure 70. Global Neurometabolic Disorders Sales Forecast by Application (2025-2032)
Figure 71. Global Neurometabolic Disorders Market Share Forecast by Application (2025-2032)
